Ultragenyx Pharmaceutical received full FDA approval for FAYUVI, the first treatment for Sanfilippo syndrome Type A, an ultra-rare and fatal childhood disease. This approval is a significant milestone for the company, marking its second gene therapy success and including a valuable Priority Review Voucher, leading to a substantial after-hours stock jump.
Ultragenyx Pharmaceutical (RARE) experienced a significant stock surge following the FDA's full approval of FAYUVI, a groundbreaking gene therapy for Sanfilippo syndrome Type A. This approval is a major corporate catalyst, as FAYUVI is the first-ever treatment for this ultra-rare and fatal childhood disease, opening up a new market for Ultragenyx. The inclusion of a Priority Review Voucher further enhances the value, as these can be sold for hundreds of millions of dollars or used to expedite future drug reviews. This event is a strong positive for RARE, demonstrating successful R&D and regulatory navigation, and could lead to substantial revenue generation and improved investor confidence in the short and long term, despite the stock's previous 12-month decline.